JP2008513744A - 腫瘍疾患および慢性炎症性腸疾患の診断のための液性バイオマーカーとしてのカルバモイルリン酸合成酵素1(cps1)の使用 - Google Patents
腫瘍疾患および慢性炎症性腸疾患の診断のための液性バイオマーカーとしてのカルバモイルリン酸合成酵素1(cps1)の使用 Download PDFInfo
- Publication number
- JP2008513744A JP2008513744A JP2007531659A JP2007531659A JP2008513744A JP 2008513744 A JP2008513744 A JP 2008513744A JP 2007531659 A JP2007531659 A JP 2007531659A JP 2007531659 A JP2007531659 A JP 2007531659A JP 2008513744 A JP2008513744 A JP 2008513744A
- Authority
- JP
- Japan
- Prior art keywords
- cps1
- inflammatory bowel
- chronic inflammatory
- bowel disease
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 83
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 29
- 230000001684 chronic effect Effects 0.000 title claims abstract description 27
- 239000000090 biomarker Substances 0.000 title claims abstract description 14
- 238000003745 diagnosis Methods 0.000 title claims description 20
- 101000855412 Homo sapiens Carbamoyl-phosphate synthase [ammonia], mitochondrial Proteins 0.000 title abstract description 100
- 102100026422 Carbamoyl-phosphate synthase [ammonia], mitochondrial Human genes 0.000 title abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 28
- 238000001514 detection method Methods 0.000 claims abstract description 17
- 210000002966 serum Anatomy 0.000 claims abstract description 12
- 239000012634 fragment Substances 0.000 claims abstract description 11
- 230000005965 immune activity Effects 0.000 claims abstract description 7
- 238000013399 early diagnosis Methods 0.000 claims abstract description 6
- 238000000338 in vitro Methods 0.000 claims abstract description 5
- 238000005259 measurement Methods 0.000 claims description 37
- 210000002381 plasma Anatomy 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 101710113083 Carbamoyl-phosphate synthase Proteins 0.000 claims 13
- 101000983292 Homo sapiens N-fatty-acyl-amino acid synthase/hydrolase PM20D1 Proteins 0.000 abstract 5
- 101000861263 Homo sapiens Steroid 21-hydroxylase Proteins 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000439 tumor marker Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 206010040047 Sepsis Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241001494479 Pecora Species 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 230000004143 urea cycle Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 102000049167 human CPS1 Human genes 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000012123 point-of-care testing Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 2
- 206010020575 Hyperammonaemia Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 101000859568 Methanobrevibacter smithii (strain ATCC 35061 / DSM 861 / OCM 144 / PS) Carbamoyl-phosphate synthase Proteins 0.000 description 2
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 231100000354 acute hepatitis Toxicity 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000007479 molecular analysis Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000010421 standard material Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 101150018690 CPS2 gene Proteins 0.000 description 1
- 108090000447 Carbamoyl-phosphate synthase (ammonia) Proteins 0.000 description 1
- 102000037115 Carbamoyl-phosphate synthase (ammonia) Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101100020327 Salvia divinorum KPS gene Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZDVWPPFTKCGYBB-UHFFFAOYSA-N [4-[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]phenyl] 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC(C=C1)=CC=C1CCC(=O)ON1C(=O)CCC1=O ZDVWPPFTKCGYBB-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- FFQKYPRQEYGKAF-UHFFFAOYSA-N carbamoyl phosphate Chemical compound NC(=O)OP(O)(O)=O FFQKYPRQEYGKAF-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
正常健常者および腫瘍患者におけるヒト血漿中のCPS1の免疫活性測定
1.1ペプチド合成
ヒトCPS1の既知のアミノ酸配列に由来する2つの領域を選択した(Pos.184〜199:ペプチド領域1;配列番号1;Pos.245〜257:ペプチド領域1;配列番号2)。いずれの場合もN末端のシステイン残基を補充して、両方の領域は、可溶ペプチドとして標準的方法によって、化学的に合成し、精製し、質量分析および逆相HPLCによって精度管理を実施し、一定分量で冷凍乾燥した(JERINI AG, Berlin, Germany)。ペプチドのアミノ酸配列は以下の通りであった。
ペプチドPCEN17:CEFEGQPVDFVDPNKQN配列番号1
ペプチドPCVD14:CVPWNHDFTKMEYD配列番号2
上記のペプチドPCEN17およびPCVD14を、MBS(m-マレイミドベンゾイル-N-ヒドロキシサクシンイミドエステル)(参照、PIERCEの作業手順「NHS-エステル-マレイミド架橋剤」米国イリノイ州ロックフォード)によって担体タンパク質KLH(キーホールリンペットヘモシアニン)と組合せた(conjugated)。以下の計画に従って、これらの組合せ体によりヒツジを免疫した。それぞれのヒツジに対して、最初に組合せ体100μg(組合せ体のペプチド画分に基づく一定量)を投与し、それから4週毎に組合せ体50μg(組合せ体のペプチド画分に基づく一定量)を投与した。免疫化開始の4カ月後から開始して、4週毎にヒツジあたり700mlの血液を採取し、そこから遠心によって抗血清を得た。組合せ、免疫化および抗血清の回収は、MicroPharm(英国カマーゼンシア)によって実施した。
ペプチド特異抗体は、免疫化の4カ月後から開始して採取した抗血清から一段階による方法で調製した。
精製抗PCEN17抗体(上記参照)500μlを作業手順に従って、NAP-5ゲル濾過カラム(Pharmacia)を通して、100mMリン酸カリウム緩衝液(pH8.0)1mlにより再度緩衝した。抗体溶液のタンパク質濃度測定から1.5mg/mlの値が得られた。
照射した5mlポリスチレン試験管(Greiner製)を下記のように精製抗PCVD14抗体でコーティングした。抗体を50mMTris、100mMNaCl、pH7.8で6.6μg/mlの濃度に希釈した。溶液300μlをピペットでそれぞれの試験管に加えた。試験管を22℃で20時間インキュベートした。溶液を吸引濾過した。次に、それぞれの試験管を4.2mlの10mMリン酸ナトリウム、2%Karion FP、0.3%ウシ血清アルブミン、pH6.5で満たした。20時間後、溶液を吸引濾過した。最後に、試験管を真空乾燥機で乾燥させた。
2.1アッセイデザイン
下記の組成のアッセイ緩衝液を作製した。
100mMリン酸ナトリウム、150mMNaCl、5%ウシ血清アルブミン、0.1%非特異的ヒツジIgG、0.1%アジ化ナトリウム、pH7.4。
試験血清
a.CPS1測定に使用した試験血清は、まず第一に、さまざまな器官/組織の臨床的に診断されたさまざまな腫瘍患者の557個の血漿であった。それぞれの試験血漿に対して、正確な臨床文書が存在し、これにより患者で発見された腫瘍タイプに応じて、測定で使用された患者の血漿の項目別分類が可能であった。
大腸癌72%
肝臓癌38%
腎臓癌85%
膵臓癌48%
肺癌42%
乳癌24%。
Claims (8)
- 腫瘍疾患および慢性炎症性腸疾患のin vitroでの診断、ならびに進行および治療のモニタリングのための液性バイオマーカーとしてのカルバモイルリン酸合成酵素(CPS1)および/またはCPS1免疫活性を有する断片の使用。
- 腫瘍疾患および慢性炎症性腸疾患の早期診断および検出、進行予測および重症度の評価、ならびに治療に付随する進行評価のためのin vitroでの方法であって、CPS1および/またはCPS1免疫活性を有する生理的に発生するその断片の存在および/または量を患者の血清または血漿試料において測定し、結論が腫瘍疾患または慢性炎症性腸疾患の存在、予期される進行、重症度または治療の成功に関して、CPS1またはCPS1免疫活性の検出および/または量から導き出されることを特徴とする方法。
- 測定に使用されるCPS1配列が、完全なCPS1配列のアミノ酸1から約630までを含むCPS1のN末端部分に由来する配列であることを特徴とする請求項2に記載の方法。
- 免疫診断アッセイ法であることを特徴とする請求項2および3のいずれかに記載の方法。
- 癌患者または慢性炎症性腸疾患患者の全血、血清または血漿試料で、CPS1酵素活性またはCPS1残存酵素活性を測定するための方法であることを特徴とする請求項2および3のいずれかに記載の方法。
- 大腸癌、肝臓癌、膵臓癌、肺癌および乳癌、ならびにその組み合わせからなる群から選択される癌腫を検出するために実施することを特徴とする請求項2から5のいずれかに記載の方法。
- クローン病(Enteritis regionalis)および潰瘍性大腸炎から選択される慢性炎症性腸疾患の診断または進行もしくは治療のモニタリングで実施することを特徴とする請求項2から5のいずれかに記載の方法。
- 癌疾患および慢性炎症性腸疾患を治療するための薬物の調製のためのCPS1阻害剤の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004045705.0 | 2004-09-21 | ||
DE102004045705A DE102004045705A1 (de) | 2004-09-21 | 2004-09-21 | Verwendungen der Carbamoylphosphat Synthetase 1(CPS) als humoraler Biomarker für die Diagnose von Tumorerkrankungen und chronisch entzündlichen Darmerkrankungen |
PCT/EP2005/009827 WO2006032392A2 (de) | 2004-09-21 | 2005-09-13 | Verwendungen der carbamoylphosphat sythetase 1 (cps 1) als humoraler biomarker für die diagnose von tumorerkrankungen und chronisch entzündlichen darmerkrankungen |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008513744A true JP2008513744A (ja) | 2008-05-01 |
JP4795353B2 JP4795353B2 (ja) | 2011-10-19 |
Family
ID=35447594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007531659A Active JP4795353B2 (ja) | 2004-09-21 | 2005-09-13 | 腫瘍疾患および慢性炎症性腸疾患の診断のための液性バイオマーカーとしてのカルバモイルリン酸合成酵素1(cps1)の使用 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20110165596A1 (ja) |
EP (1) | EP1792186B1 (ja) |
JP (1) | JP4795353B2 (ja) |
DE (2) | DE102004045705A1 (ja) |
ES (1) | ES2330239T3 (ja) |
WO (1) | WO2006032392A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009536327A (ja) * | 2006-05-08 | 2009-10-08 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | 薬剤誘導肝臓損傷及び中毒性物質誘導肝臓損傷の同定及び早期同定並びに治療の同時観察のためのinvitro方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10260111B1 (en) | 2014-01-20 | 2019-04-16 | Brett Eric Etchebarne | Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005523028A (ja) * | 2002-04-19 | 2005-08-04 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | 炎症性疾患および敗血症を診断するための、カルバモイルリン酸シンテターゼ1(cps1)およびその断片の使用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4822733A (en) * | 1985-05-28 | 1989-04-18 | Amoco Corporation | Lifetime-resolved assay procedures |
FR2664699B1 (fr) * | 1990-07-13 | 1995-08-18 | Cis Bio Int | Procede d'amplification du signal d'emission d'un compose luminescent. |
DE4227454C1 (de) | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
CA2329146A1 (en) * | 1998-06-01 | 1999-12-09 | Incyte Pharmaceuticals, Inc. | Carbamoyl phosphate synthase homolog |
DE19847690A1 (de) * | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
WO2003042661A2 (en) * | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
EP1403282A1 (en) * | 2002-09-26 | 2004-03-31 | Cellzome Ag | Protein complexes of the Tumor necrosis factor-alpha (TNF-alpha) signalling pathway |
-
2004
- 2004-09-21 DE DE102004045705A patent/DE102004045705A1/de not_active Ceased
-
2005
- 2005-09-13 DE DE502005007715T patent/DE502005007715D1/de active Active
- 2005-09-13 JP JP2007531659A patent/JP4795353B2/ja active Active
- 2005-09-13 ES ES05783050T patent/ES2330239T3/es active Active
- 2005-09-13 WO PCT/EP2005/009827 patent/WO2006032392A2/de active Application Filing
- 2005-09-13 EP EP05783050A patent/EP1792186B1/de active Active
- 2005-09-13 US US11/575,603 patent/US20110165596A1/en not_active Abandoned
-
2011
- 2011-01-07 US US12/986,385 patent/US8426180B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005523028A (ja) * | 2002-04-19 | 2005-08-04 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | 炎症性疾患および敗血症を診断するための、カルバモイルリン酸シンテターゼ1(cps1)およびその断片の使用 |
Non-Patent Citations (1)
Title |
---|
JPN5007015800, LIU T−H, CHINESE MEDICAL JOURNAL (ENGLISH EDITION), 1989, V102 N8, P630−638 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009536327A (ja) * | 2006-05-08 | 2009-10-08 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | 薬剤誘導肝臓損傷及び中毒性物質誘導肝臓損傷の同定及び早期同定並びに治療の同時観察のためのinvitro方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1792186B1 (de) | 2009-07-15 |
EP1792186A2 (de) | 2007-06-06 |
US8426180B2 (en) | 2013-04-23 |
JP4795353B2 (ja) | 2011-10-19 |
DE102004045705A1 (de) | 2006-04-06 |
US20110165596A1 (en) | 2011-07-07 |
ES2330239T3 (es) | 2009-12-07 |
WO2006032392A2 (de) | 2006-03-30 |
DE502005007715D1 (de) | 2009-08-27 |
US20120077208A1 (en) | 2012-03-29 |
WO2006032392A3 (de) | 2006-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022141755A (ja) | 膵臓がんを検出するための方法および組成物 | |
US7361474B2 (en) | Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer | |
JP5006802B2 (ja) | 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのCyr61 | |
KR101032607B1 (ko) | 간암 진단용 단백질성 마커 | |
US20080176259A1 (en) | Uses of carbamoyl phosphate synthetase 1 (cps 1) and it's fragments for the diagnosis of liver diseases | |
EP2251695B1 (en) | Markers associated with endometrial disease | |
US9086412B2 (en) | Extracellular vesicle-associated protein markers of cancer | |
US20180238890A1 (en) | Methods and materials for detection, diagnosis and management of ovarian cancer | |
WO2013104104A1 (zh) | 诊断和预示乳腺癌的标志物 | |
JP2008533454A (ja) | 炎症及び感染症のためのバイオマーカーとしての短鎖srlアルコールデヒドロゲナーゼ(dhrs4)の測定 | |
KR20130046457A (ko) | 신규한 대장암 진단용 마커 및 이를 이용한 대장암 진단 키트 | |
JP2019507594A (ja) | 大腸がん診断用組成物と診断マーカー検出方法 | |
JP5194000B2 (ja) | 薬剤誘導肝臓損傷及び中毒性物質誘導肝臓損傷の同定及び早期同定並びに治療の同時観察のためのinvitro方法 | |
JP2012507268A (ja) | バイオマーカーとしてのEEF1Aの使用およびMetAP2阻害剤をスクリーニングするための方法 | |
JP4515099B2 (ja) | Lasp−1免疫反応性の決定によって炎症性疾患および感染を診断するための方法 | |
JP4795353B2 (ja) | 腫瘍疾患および慢性炎症性腸疾患の診断のための液性バイオマーカーとしてのカルバモイルリン酸合成酵素1(cps1)の使用 | |
JP7432578B2 (ja) | がんマーカーおよびその用途 | |
US20080227098A1 (en) | Method for diagnosing cancer of the prostate | |
KR101815253B1 (ko) | 간 섬유화 진단용 바이오마커 cxcl14 | |
JP2002526760A (ja) | 消化器癌を診断、監視、病期分類、イメージング及び治療する新規な方法 | |
KR101567053B1 (ko) | 방사선 피폭에 의한 간 손상 예측용 바이오마커 및 그 예측방법 | |
KR101901457B1 (ko) | 간암 암 줄기세포 특성에 기초한 간암의 신규 바이오마커 및 그의 용도 | |
KR100970654B1 (ko) | 대장암 진단용 키트 | |
KR101652894B1 (ko) | 대장암에 대한 신규 바이오마커 및 그의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080826 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100826 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100831 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110628 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110727 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4795353 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140805 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |